Skip to main content
. Author manuscript; available in PMC: 2022 May 9.
Published in final edited form as: Eur Urol. 2020 Jul 2;78(5):661–669. doi: 10.1016/j.eururo.2020.06.043

Table 2 –

Descriptive preoperative characteristics of patients related to salvage lymph node dissection (sLND).

Variable Overall population (n = 189; 100%)
Time from RP to PSA rising (mo) 22 (7, 38)
Type of PET/CT tracer, n (%)
11C-choline 154 (81)
68Ga-PSMA 6 (3)
 Unknown 29 (16)
Ongoing ADT at the time of PET/CT, n (%)
 No 98 (52)
 Yes 34 (18)
 Unknown 57 (30)
Site of positive spots at PET/CT, n (%)
 Pelvic 113 (60)
 Retroperitoneal 18 (10)
 Both 27 (14)
 Unknown 31 (16)
Number of positive spots at PET/CT, n (%)
 0 9 (5)
 1 91 (48)
 2 26 (14)
 ≥3 38 (20)
 Unknown 25 (13)
Age at sLND (yr) 65 (60, 70)
PSA level at sLND (ng/mL) 2.5 (1.1, 5.4)

ADT = androgen deprivation therapy; PSA = prostate-specific antigen; PSMA = prostate-specific membrane antigen; PET/CT = positron emission tomography/computed tomography; RP = radical prostatectomy.

All numbers are medians (interquartile range) and frequencies (proportions).